Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results